Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS.

J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359. [Epub ahead of print] No abstract available.

PMID:
30359156
2.

Further studies on the application of vinylogous amides and β-halovinylaldehydes to the regiospecific synthesis of unsymmetrical, polyfunctionalized 2,3,4- and 1,2,3,4- substituted pyrroles.

Gupton JT, Shimozono A, Crawford E, Ortolani J, Clark E, Mahoney M, Heese C, Noble J, Mandry CP, Kanters R, Dominey RN, Goldman EW, Sikorski JA, Fisher DC.

Tetrahedron. 2018 May 24;74(21):2650-2663. doi: 10.1016/j.tet.2018.04.017. Epub 2018 Apr 7.

PMID:
30344350
3.

Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia.

Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR.

Leuk Lymphoma. 2018 Oct 15:1-4. doi: 10.1080/10428194.2018.1519814. [Epub ahead of print]

PMID:
30322319
4.

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators.

Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9.

PMID:
30100375
5.

Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.

Barnes JA, Redd R, Fisher DC, Hochberg EP, Takvorian T, Neuberg D, Jacobsen E, Abramson JS.

Hematol Oncol. 2018 Oct;36(4):633-637. doi: 10.1002/hon.2515. Epub 2018 Jun 28.

PMID:
29956350
6.

Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.

Dewan AK, Sowerby L, Jadeja S, Lian C, Wen P, Brown JR, Fisher DC, LeBoeuf NR.

Clin Exp Dermatol. 2018 Dec;43(8):890-894. doi: 10.1111/ced.13608. Epub 2018 May 30.

PMID:
29851132
7.

High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides.

de Masson A, O'Malley JT, Elco CP, Garcia SS, Divito SJ, Lowry EL, Tawa M, Fisher DC, Devlin PM, Teague JE, Leboeuf NR, Kirsch IR, Robins H, Clark RA, Kupper TS.

Sci Transl Med. 2018 May 9;10(440). pii: eaar5894. doi: 10.1126/scitranslmed.aar5894.

PMID:
29743350
8.

Holen et al. reply.

Holen SR, Deméré TA, Fisher DC, Fullagar R, Paces JB, Jefferson GT, Beeton JM, Cerutti RA, Rountrey AN, Vescera L, Holen KA.

Nature. 2018 Feb 7;554(7691):E3. doi: 10.1038/nature25166. No abstract available.

PMID:
29420475
9.

Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.

Sun L, Li S, El-Jawahri A, Armand P, Dey BR, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, McAfee SL, Spitzer TR, Chen YB, DeFilipp Z.

Oncologist. 2018 May;23(5):624-630. doi: 10.1634/theoncologist.2017-0499. Epub 2017 Dec 28.

PMID:
29284757
10.
11.

A 130,000-year-old archaeological site in southern California, USA.

Holen SR, Deméré TA, Fisher DC, Fullagar R, Paces JB, Jefferson GT, Beeton JM, Cerutti RA, Rountrey AN, Vescera L, Holen KA.

Nature. 2017 Apr 26;544(7651):479-483. doi: 10.1038/nature22065.

PMID:
28447646
12.

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.

Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, Armand P, Alyea EP, Koreth J, Ho V, Soiffer RJ, Antin JH, Ritz J, Nikiforow S, Forman SJ, Michor F, Neuberg D, Bhatia R, Bhatia S, Ebert BL.

J Clin Oncol. 2017 May 10;35(14):1598-1605. doi: 10.1200/JCO.2016.71.6712. Epub 2017 Jan 9.

13.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P.

J Clin Oncol. 2017 Jan;35(1):24-31. Epub 2016 Oct 24.

14.

Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy (alemtuzumab).

Clark SL, Tse JY, Fisher DC, LeBeouf NR, Murphy GF, Kupper TS, Clark RA, Lian CG.

J Cutan Pathol. 2016 Nov;43(11):989-993. doi: 10.1111/cup.12800. Epub 2016 Sep 9. Erratum in: J Cutan Pathol. 2017 Feb;44(2):220.

15.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

16.

Pre-Clovis occupation 14,550 years ago at the Page-Ladson site, Florida, and the peopling of the Americas.

Halligan JJ, Waters MR, Perrotti A, Owens IJ, Feinberg JM, Bourne MD, Fenerty B, Winsborough B, Carlson D, Fisher DC, Stafford TW Jr, Dunbar JS.

Sci Adv. 2016 May 13;2(5):e1600375. doi: 10.1126/sciadv.1600375. eCollection 2016 May.

17.

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR.

Blood. 2016 Jul 14;128(2):195-203. doi: 10.1182/blood-2016-03-707133. Epub 2016 May 31.

18.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

19.

A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.

Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, LaCasce AS, Jacobson C, Davids MS, Brown JR, Weng L, Wilkins J, Faham M, Freedman AS, Joyce R, Jacobsen ED.

Br J Haematol. 2016 Apr;173(1):89-95. doi: 10.1111/bjh.13929. Epub 2016 Jan 5.

PMID:
26729345
20.

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.

Chen YB, Li S, Fisher DC, Driscoll J, Del Rio C, Abramson J, Armand P, Barnes J, Brown J, Cutler C, El-Jawahri A, Ho VT, Hochberg E, McAfee S, Takvorian R, Spitzer TR, Antin JH, Soiffer R, Jacobsen E.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1583-8. doi: 10.1016/j.bbmt.2015.05.016. Epub 2015 May 22.

21.

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.

Brown JR, Tesar B, Yu L, Werner L, Takebe N, Mikler E, Reynolds HM, Thompson C, Fisher DC, Neuberg D, Freedman AS.

Leuk Lymphoma. 2015;56(12):3336-42. doi: 10.3109/10428194.2015.1048441. Epub 2015 Jun 18.

PMID:
25971907
22.

Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.

Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ.

Cancer Cell. 2015 Mar 9;27(3):327-41. doi: 10.1016/j.ccell.2015.02.001.

23.

Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats.

Guy EG, Fisher DC, Higgins GA, Fletcher PJ.

Behav Pharmacol. 2014 Dec;25(8):775-83. doi: 10.1097/FBP.0000000000000092.

PMID:
25230208
24.

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.

Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS.

Leuk Lymphoma. 2015 Apr;56(4):993-8. doi: 10.3109/10428194.2014.941835. Epub 2014 Aug 20.

PMID:
25012943
25.

Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission.

Watanabe R, Teague JE, Fisher DC, Kupper TS, Clark RA.

JAMA Dermatol. 2014 Jul;150(7):776-9. doi: 10.1001/jamadermatol.2013.10099. No abstract available.

26.

Thyroid lymphoma on a background of Hashimoto's thyroiditis: PET/CT appearances.

Mane M, O'Neill AC, Tirumani SH, Shi M, Shinagare AB, Fisher DC.

Clin Imaging. 2014 Nov-Dec;38(6):864-7. doi: 10.1016/j.clinimag.2014.03.004. Epub 2014 Mar 14.

PMID:
24679651
27.

An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.

Szabatura AH, Cirrone F, Harris C, McDonnell AM, Feng Y, Voit D, Neuberg D, Butrynski J, Fisher DC.

J Oncol Pharm Pract. 2015 Jun;21(3):188-93. doi: 10.1177/1078155214527143. Epub 2014 Mar 24.

PMID:
24664476
28.

Blood pressure is associated with occult cardiovascular disease in prospectively studied Hodgkin lymphoma survivors after chest radiation.

Chen MH, Blackington LH, Zhou J, Chu TF, Gauvreau K, Marcus KJ, Fisher DC, Diller LR, Ng AK.

Leuk Lymphoma. 2014 Nov;55(11):2477-83. doi: 10.3109/10428194.2013.879716. Epub 2014 Feb 27.

PMID:
24397615
29.

Evolution of high tooth replacement rates in sauropod dinosaurs.

D'Emic MD, Whitlock JA, Smith KM, Fisher DC, Wilson JA.

PLoS One. 2013 Jul 17;8(7):e69235. doi: 10.1371/journal.pone.0069235. Print 2013.

30.

Successful treatment of perianal giant condyloma acuminatum in an immunocompromised host with systemic interleukin 2 and topical cidofovir.

Nambudiri VE, Mutyambizi K, Walls AC, Fisher DC, Bleday R, Saavedra AP.

JAMA Dermatol. 2013 Sep;149(9):1068-70. doi: 10.1001/jamadermatol.2013.5160. No abstract available.

PMID:
23824272
31.

Bomb-curve radiocarbon measurement of recent biologic tissues and applications to wildlife forensics and stable isotope (paleo)ecology.

Uno KT, Quade J, Fisher DC, Wittemyer G, Douglas-Hamilton I, Andanje S, Omondi P, Litoroh M, Cerling TE.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11736-41. doi: 10.1073/pnas.1302226110. Epub 2013 Jul 1.

32.

Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.

Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS.

Br J Haematol. 2013 Oct;163(1):123-6. doi: 10.1111/bjh.12439. Epub 2013 Jun 25. No abstract available.

PMID:
23795711
33.

TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.

Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, Fisher DC, Kupper TS, Clark RA.

Clin Cancer Res. 2013 Jul 15;19(14):3755-63. doi: 10.1158/1078-0432.CCR-12-3488. Epub 2013 Jun 19.

34.

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS.

Haematologica. 2013 Jun;98(6):964-70. doi: 10.3324/haematol.2013.086207. Epub 2013 May 3.

35.

Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma.

Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, Silver B, Fisher DC, Marcus KJ, Mauch PM.

J Clin Oncol. 2013 Jun 20;31(18):2282-8. doi: 10.1200/JCO.2012.46.5732. Epub 2013 Apr 22.

PMID:
23610104
36.

Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, Verrill KA, Kleinjan JA, Patel A, Zhang Y, Hill H, Acharyya A, Fisher DC, Antin JH, Seaman MS, Dolin R, Baden LR.

J Infect Dis. 2013 Jun 15;207(12):1888-97. doi: 10.1093/infdis/jit105. Epub 2013 Mar 12.

37.

Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study.

Abramson JS, Takvorian RW, Fisher DC, Feng Y, Jacobsen ED, Brown JR, Barnes JA, Neuberg DS, Hochberg EP.

Leuk Lymphoma. 2013 Sep;54(9):1915-20. doi: 10.3109/10428194.2013.763397. Epub 2013 Jan 30.

38.

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.

Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB.

Br J Haematol. 2013 Mar;160(5):608-17. doi: 10.1111/bjh.12176. Epub 2012 Dec 29.

PMID:
23278720
39.

Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.

Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, Armand P, Joyce R, Sohani AR, Rodig SJ, Neuberg D, Fisher DC, Abramson JS.

Haematologica. 2013 Apr;98(4):615-9. doi: 10.3324/haematol.2012.075184. Epub 2012 Nov 9.

40.

Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.

Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, Koreth J, Ritz J, Wu C, Antin JH, Soiffer RJ, Gribben JG, Alyea EP.

Leukemia. 2013 Feb;27(2):362-9. doi: 10.1038/leu.2012.228. Epub 2012 Aug 14.

41.

Full facial edema: a novel presentation of subcutaneous panniculitis-like T-cell lymphoma.

Velez NF, Ishizawar RC, Dellaripa PF, Saavedra AP, Laga AC, Murphy GF, Fisher DC, Kupper TS, Vleugels RA.

J Clin Oncol. 2012 Sep 1;30(25):e233-6. doi: 10.1200/JCO.2011.40.7684. Epub 2012 Jul 23. No abstract available.

PMID:
22826278
42.

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.

Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM.

Cancer Discov. 2012 Jan;2(1):47-55. doi: 10.1158/2159-8290.CD-11-0208. Epub 2011 Dec 12.

43.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M.

Blood. 2012 May 3;119(18):4115-22. doi: 10.1182/blood-2011-11-390211. Epub 2012 Mar 6.

44.

Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.

Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, Dorosario AA, Chaney KS, Cutler CS, Leboeuf NR, Carter JB, Fisher DC, Kupper TS.

Sci Transl Med. 2012 Jan 18;4(117):117ra7. doi: 10.1126/scitranslmed.3003008.

45.

Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy.

McDonnell AM, Rybak I, Wadleigh M, Fisher DC.

J Oncol Pharm Pract. 2012 Dec;18(4):436-9. doi: 10.1177/1078155211433231. Epub 2012 Jan 10.

PMID:
22235061
46.

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.

Lane AA, Armand P, Feng Y, Neuberg DS, Abramson JS, Brown JR, Fisher DC, LaCasce AS, Jacobsen ED, McAfee SL, Spitzer TR, Freedman AS, Chen YB.

Leuk Lymphoma. 2012 Jun;53(6):1130-6. doi: 10.3109/10428194.2011.645208. Epub 2012 Jan 3.

47.

Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.

Fox AM, Dosoretz AP, Mauch PM, Chen YH, Fisher DC, LaCasce AS, Freedman AS, Silver B, Ng AK.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):277-83. doi: 10.1016/j.ijrobp.2011.05.078. Epub 2011 Oct 20.

PMID:
22019238
48.

Symptomatic extranodal Rosai-Dorfman disease treated with steroids, radiation, and surgery.

Saboo SS, Jagannathan JP, Krajewski KM, O'Regan K, Hornick JL, Fisher DC, Ramaiya N.

J Clin Oncol. 2011 Nov 1;29(31):e772-5. doi: 10.1200/JCO.2011.36.9967. Epub 2011 Sep 19. No abstract available.

PMID:
21931038
49.

Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.

Cote GM, Hochberg EP, Muzikansky A, Hochberg FH, Drappatz J, McAfee SL, Batchelor TT, LaCasce AS, Fisher DC, Abramson JS, Armand P, Chen YB.

Biol Blood Marrow Transplant. 2012 Jan;18(1):76-83. doi: 10.1016/j.bbmt.2011.07.006. Epub 2011 Jul 13.

50.

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.

Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg D, Brown JR.

Clin Cancer Res. 2011 May 1;17(9):2977-86. doi: 10.1158/1078-0432.CCR-10-2879. Epub 2011 Mar 14.

Supplemental Content

Loading ...
Support Center